- Home
- LRMR
as 12-18-2024 12:39pm EST
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BALA CYNWYD |
| Market Cap: | 426.9M | IPO Year: | N/A |
| Target Price: | $19.63 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.01 - $13.68 | Next Earning Date: | 10-30-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Larimar Therapeutics Inc. News
LRMR Breaking Stock News: Dive into LRMR Ticker-Specific Updates for Smart Investing
TipRanks
a day ago
Larimar Therapeutics announces initial data from OLE study of nomlabofusp
GlobeNewswire
2 days ago
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia
GlobeNewswire
a month ago
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
GlobeNewswire
2 months ago
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Simply Wall St.
2 months ago
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
GlobeNewswire
3 months ago
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
GlobeNewswire
4 months ago
Larimar Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
4 months ago
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Compare LRMR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LRMR Larimar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.